<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9344">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05699993</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI351P003</org_study_id>
    <nct_id>NCT05699993</nct_id>
  </id_info>
  <brief_title>A Study of IBI351 in Healthy Subjects</brief_title>
  <official_title>An Open-label, 2-cycle Clinical Study to Evaluate the Drug Interaction Between Itraconazole or Dextromethorphan and IBI351 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, two-cycle clinical study to evaluate the drug interaction between&#xD;
      itraconazole or dextromethorphan and IBI351 in healthy subjects. A total of two cohorts of 12&#xD;
      healthy male subjects were planned to be enrolled in each cohort.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 27, 2023</start_date>
  <completion_date type="Anticipated">May 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 25, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum concentrations (Cmax ) for IBI351</measure>
    <time_frame>approximately 10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>maximum concentrations (Cmax ) for dextromethorphan</measure>
    <time_frame>approximately 10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the curve from time 0 to infinity(AUC0-inf) for IBI351</measure>
    <time_frame>approximately 10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the curve from time 0 to infinity(AUC0-inf) for dextromethorphan</measure>
    <time_frame>approximately 10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time-to-maximum concentration (Tmax) for IBI351</measure>
    <time_frame>approximately 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>half-life (t1/2) for IBI351</measure>
    <time_frame>approximately 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the curve from time 0 to time (AUC0-t) for IBI351</measure>
    <time_frame>approximately 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apparent clearance (CL/F) for IBI351</measure>
    <time_frame>approximately 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apparent volume of distribution(Vz/F) for IBI351</measure>
    <time_frame>approximately 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time-to-maximum concentration (Tmax) for dextromethorphan</measure>
    <time_frame>approximately 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>half-life (t1/2) for dextromethorphan</measure>
    <time_frame>approximately 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the curve from time 0 to time (AUC0-t) for dextromethorphan</measure>
    <time_frame>approximately 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apparent clearance (CL/F) for dextromethorphan</measure>
    <time_frame>approximately 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apparent volume of distribution(Vz/F) for dextromethorphan</measure>
    <time_frame>approximately 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the curve for dextrorphan</measure>
    <time_frame>approximately 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maximum concentrations (Cmax ) for dextrorphan</measure>
    <time_frame>approximately 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with abnormal hematology tests</measure>
    <time_frame>approximately 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with abnormal chemistry parameters</measure>
    <time_frame>approximately 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with abnormal vital signs</measure>
    <time_frame>approximately 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with abnormal physical examination findings</measure>
    <time_frame>approximately 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with abnormal ECG readings</measure>
    <time_frame>approximately 10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>IBI351+ itraconazole</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Enrolled subjects were treated with IBI351 on an empty stomach on Day 1. Itraconazole was administered orally once daily after a standardized meal from Day 3 to Day 6. IBI351 and itraconazole were administered simultaneously on an empty stomach on Day 7. On Day 8, itraconazole was orally administered once after a standard meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI351+ dextromethorphan</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Enrolled subjects were orally administered dextromethorphan on an empty stomach on Day 1. IBI351 and dextromethorphan were orally administered simultaneously on an empty stomach on Day 3, followed by IBI351 12 hours later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Itraconazole was administered orally</description>
    <arm_group_label>IBI351+ itraconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI351</intervention_name>
    <description>IBI351 was administered orally</description>
    <arm_group_label>IBI351+ dextromethorphan</arm_group_label>
    <arm_group_label>IBI351+ itraconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan</intervention_name>
    <description>Dextromethorphan was administered orally</description>
    <arm_group_label>IBI351+ dextromethorphan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily sign the informed consent form before the trial, fully understand the&#xD;
             content, process and possible adverse reactions of the trial, and be able to complete&#xD;
             the study according to the requirements of the trial protocol.&#xD;
&#xD;
          2. Healthy male subjects aged 18 to 45 years (including both ends) at the time of signing&#xD;
             informed consent.&#xD;
&#xD;
          3. Body weight is not less than 50 kg, and body mass index (BMI) is in the range of 19 ~&#xD;
             26 kg/m2 (including both ends).&#xD;
&#xD;
          4. Physical examination, vital signs, routine laboratory tests (blood routine, blood&#xD;
             biochemistry, urine routine, coagulation function), thyroid function, 12-lead&#xD;
             electrocardiogram, chest CT, abdominal ultrasound (hepatobiliary, pancreatic, spleen&#xD;
             and kidney), echocardiography (only applicable to Cohort 1 subjects) showed no&#xD;
             abnormalities; or abnormal test results but judged as normal or clinically&#xD;
             insignificant by the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. have taken any products containing alcohol or have a positive alcohol breath test (â‰¥&#xD;
             20 mg/100 ml) within 24 hours before taking study medication.&#xD;
&#xD;
          2. hepatitis B surface antigen HBsAg positive.&#xD;
&#xD;
          3. hepatitis C virus antibody positive.&#xD;
&#xD;
          4. positive AIDS antigen/antibody or Treponema pallidum antibody.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Haiyan Zhu</last_name>
    <phone>0512-69566088</phone>
    <email>haiyan.zhu@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Suzhou University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 17, 2023</study_first_submitted>
  <study_first_submitted_qc>January 25, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2023</study_first_posted>
  <last_update_submitted>January 25, 2023</last_update_submitted>
  <last_update_submitted_qc>January 25, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

